Health Condition 1: L819- Disorder of pigmentation, unspecified
Conditions
Interventions
None listed
Sponsors
HOUSE OF ADITI PRIVATE LIMITED
Eligibility
Inclusion criteria
Inclusion criteria: 1. Clinically diagnosed mild to moderate facial hyperpigmentation, facial solar lentigines, melasma, post inflammatory hyperpigmentation, periorbital hyperpigmentation, post acne dark spots. 2. Willing to comply with all requirements of the study including being photographed, at baseline and following post treatment care and attending all treatment and follow up visits.
Exclusion criteria
Exclusion criteria: 1. Subjects who have received facial treatments within the past three months 2. Subjects with a known current history of chronic skin diseases or autoimmune diseases, such as atopic dermatitis, psoriasis, chronic urticaria, vitiligo and rosacea 3. Subjects who have used facial blemish-lightening products, topical or oral whitening drugs within 21 days before entering the trial 4. Subjects on any other investigational products within 1 month prior to randomization 5. Subjects with known current tuberculosis, HIV, ischemic heart disease, cancer, kidney failure. 6. Pregnant women 7. Known hypersensitivity to any of the ingredients of Desa Kumkumadi Taila 8. Dosage and Treatment Duration Other conditions, which in the opinion of the investigators, make patient unsuitable for enrolment or could interfere with his or her participation in, and completion of the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in facial hyperpigmentation spotTimepoint: Baseline visit (day 0), day 15 and end of study visit (Day 30) | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Changes in photographic evaluation of Facial hyperpigmentation spot. 2. Change in skin lightening effect 3. Change in skin glow 4. Assessment of 24 hours skin patch test 5. Change in facial cutaneous moisturization 6. Changes in facial wrinkles (periorbital and perioral) 7. Difference in number of comedones (blackheads and whiteheads) on the face 8. Assessment of ability of Desa Kumkumadi oil to absorb into the skin 9. Assessment of oily or greasy appearance of skin after application of oil 10. Assessment of feeling of oil on skin 11. Global assessment for overall change by participants and by physician 12. Assessment of post treatment tolerability of study drug by participants and physician. 13. Assessment of adverse events, adverse drug reactions including vitals Timepoint: Baseline visit (day 0), day 15 and end of study visit (Day 30) | — |
Countries
India
Contacts
Public ContactDr Sanjay Tamoli
Target Institute of Medical Education and Research Pvt. Ltd
Outcome results
None listed